




**INNOVATIVE MEDICAL
SOLUTIONS FOR COVID-19**

**CORPORATE
PRESENTATION**

COVID-19 – Global Picture

+8.8 million of cases


Source: The NY Times
(as of June 21, 2020)



- 1918 Pandemic (H1N1 Virus) infected 500 million people or 1/3 of the planet and 50 million people died.
- Harvard epidemiologist Marc Lipsitch predicted that the coronavirus could infect between **40% and 70% of the world's adult population** — at least 3 billion people.

COVID-19 Overview

“The pathogenesis of COVID-19 is poorly understood, the similar mechanisms of SARS-CoV and MERS-CoV still can give us a lot of information on the pathogenesis of SARS-CoV-2 infection to facilitate our recognition of COVID-19.”



Current Research Initiatives

The COVID-19 pandemic has created a global race among pharmaceutical companies to find a cure and treatments for this deadly virus. The following table summarizes the main clinical trials that are currently underway.

Drug	Current use	Original mode of action
Colchicine	Gout	Anti-inflammatory
Virazole (ribavirin)	Respiratory syncytial virus	Synthetic nucleoside
Chloroquine	Antimalarial	Heme polymerase inhibitor
Kaletra (ritonavir+lopinavir)	HIV	Protease inhibitor
Interferon alfa-2b	Hepatitis-C	Immune modulator
Remdesivir	Experimental	Nucleotide analogue
Favipiravir	Influenza	RNA polymerase inhibitor
Actemra (tocilizumab)	Rheumatoid arthritis; COVID-19	Anti-inflammatory
Kevzara (sarilumab)	Rheumatoid arthritis	Anti-inflammatory

<https://clinicaltrials.gov/ct2/results?cond=COVID-19>

COVID-19 Strategies

- **Vaccines in 12-18-24 months from now**
- **antivirals**
- **drugs that dampen an overly aggressive immune response**
- **antibodies** derived from patients' plasma who have recovered from COVID-19 (supply and intravenous delivery will be an issue here if one of these is proven effective)
- **anything else that might work !**


Company Profile

Pulmonem Inc. was founded in 2020 by Dr. Houfar Sekhavat for the purpose of finding solutions to the COVID-19 pandemic by leveraging the expertise of the entire team of Pulmonem's sister company, **Triple Hair Inc.**

Pulmonem is a clinical-stage biotech startup whose mission is to provide solutions to infectious disease pandemics by **repurposing existing drugs** to address specific unmet medical needs. Pulmonem's COVID-19 strategy is to demonstrate, in collaboration with the **McGill University Health Center Research Institute**, the efficacy and safety of a prophylactic oral treatment using a reformulated generic drug to inhibit the development of inflammation caused by COVID-19-related infection, via the **DAP-CORONA Phase 3 clinical trial**.

Pulmonem is also pursuing solutions for the pediatric market, as well as alternative delivery systems, such as nasal sprays and liquids.

Roadmap to Saving Lives



Solid Management Team

Houfar Sekhvat, MD

Founder, President and CEO

- Ophthalmologist, serial entrepreneur and innovator.
- Currently founder of Triple Hair (hair growth therapies) and Hexiris Pharma (treatment of glaucoma).

Erika Tremblay-Gagnon, CPA CA, M.Sc.

Chief Financial Officer

- Over 14 years of financial executive experience, mainly as VP, Corporate Finance with TSX-listed Stingray Group and Senior Manager, Audit and Certification at PricewaterhouseCoopers.

Jean-Philippe Gravel, MBA

Co-Founder and Chief Operating Officer

- Over 15 years of experience in management and business development mainly with medical, pharmaceutical and natural health product companies.
- Currently President and CEO of Triple Hair.

Satish Asotra, Ph.D., MBA

Chief Manufacturing and Regulatory Officer

- Senior executive and strategic leader with a proven track record of driving pharmaceutical development, innovation and process improvement with 25 years of experience, including more than 12 years in topical and dermatological product development, with Avicanna, AHI, Accucaps, Odan Laboratories and Taro Pharmaceuticals.

Bruno Battistini, BSc, MSc, PhD-Pharmacology

Co-Founder and Chief Clinical and Government Affairs Officer

- Accomplished health care researcher, former professor of medicine, entrepreneur, senior executive and administrator whose background in pharmacology has resulted in a broad range of experience working with universities, government agencies and health foundations.

Attila Hajdu, M.Sc., MBA

Vice President, Business Development

- Accomplished leader with over 20 years of experience years in the global pharmaceutical and biotechnology industry, mainly in business development, sales, marketing, finance and medical affairs with XCO Tech, Stelvia Therapeutics, Sirona Biochem, GlaxoSmithKline and Astellas Pharma.

Research Supported by McGill University

Jean Bourbeau, MD, MSc, FRCPC

Nominated Principal Investigator

- Director, McConnell Centre for Innovative Medicine (CIM), Research Institute of the McGill University Health Centre (RI-MUHC).
- Respiriologist and Professor in the Departments of Medicine and Epidemiology & Biostatistics at McGill University.
- His areas of research and expertise are in chronic obstructive pulmonary disease, rehabilitation, disease and self-management, health and behavior, and clinical evaluative research.

Ramy Saleh, MD, MSc, FRCPC

Co-Principal Investigator

- Department of Oncology, McGill University Health Centre (MUHC), RI-MUHC Junior Scientist, Harvard T.H. Chan School of Public Health, Phase I/II trialist & clinical platform specialist for RCTs.

Andrea Benedetti, PhD

Investigator

- Associate Professor, Department of Medicine and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, RECRU-MUHC.

Sharmistha Biswas, PhD candidate, MBBS, MBA, MSc

Investigator

- Research, Respiratory Epidemiology and Clinical Research Unit (RECRU), McGill University Health Centre (MUHC).

Bryan Ross, MD, MSc, FRCPC

Investigator

- MUHC-based fellow and Respirologist, Junior Scientist, RI-MUHC.

Our Solution

- Prophylaxis approach
- The reformulated generic drug we are testing has been used as an anti-inflammatory drug
- It is also used to treat malaria, lupus, HIV and pneumocystis jirovecii pneumonia
- Phase 3 clinical trial will start in June 2020 with 2,100 patients
- Pulmonem is the first biotech company to test this drug

We believe that Pulmonem's newly patented oral medication can **alleviate – even prevent – the pulmonary inflammatory phase** and **prevent the hospitalization of many COVID-19 patients** around the world.

Its Advantages

- Our solution has a **scientifically sound mechanism of action** validated by the McGill University Health Center Research Institute.
- The drug we are testing is a **generic drug**, and hence **affordable**.
- The drug is efficiently absorbed (70%-80%) from the gastrointestinal tract and is therefore suitable to **outpatient settings**.
- It reaches peak serum concentration in 2-6 hours and has a mean half-life of 20-30 hours.
- It is well distributed to the fluid of the alveolar spaces.
- Its metabolic, pharmacokinetic and toxicological profiles are **well documented**.

Potential Investment Opportunities

- Grants
- Loans
- Equity investment
- Royalties on global sales
- Other future prospects of mutual interest

In Conclusion

- Pulmonem is pursuing a **science-based solution** (drug and protocol validated by the McGill University research team) that is **economically attractive** (low-cost generic drug), and has the **know-how and scientific knowledge** to find the answer to COVID-19.
- If we want to save lives, time is of the essence: **invest in Pulmonem** and we can fight the virus together.



www.pulmonem.ca

info@pulmonem.ca